[Prescription of new HCV-drugs - what has to be considered judicially].

  • Stefan Mauss
  • Published 2015 in Zeitschrift fur Gastroenterologie


A unique specialty of the German public health insurance system is the option to hold a physician liable for the cost of medication considered not to be in line with the indication or to not to be used in a cost efficient way. Due to the high prices of direct acting antivirals (DAA) against the hepatitis C virus the potential financial losses are… (More)
DOI: 10.1055/s-0034-1385774